Berloffa Stefano, Dosi Claudia, Tascini Benedetta, Fossati Beatrice, Lupetti Ilaria, Masi Gabriele
IRCCS Stella Maris, Scientific Institute of Child Neurology and Psychiatry, 56128 Pisa, Italy.
Department of Woman's and Children's Health, Padua University Hospital, 35128 Padua, Italy.
Children (Basel). 2021 Dec 18;8(12):1201. doi: 10.3390/children8121201.
Neuroleptic malignant syndrome (NMS) is a rare, life-threatening, idiosyncratic adverse reaction to antipsychotic drugs. Despite the increasing rates in the prescription of antipsychotics in pediatric patients with autism spectrum disorder (ASD), little is known about the occurrence and hallmarks of NMS in this specific population. NMS appears to be part of the larger catatonia domain, based on the frequent relationship between ASD and catatonia, on the shared, when not overlapping, clinical features with malignant catatonia, and on the effectiveness of catatonia treatments on the NMS/MC symptoms. The intrinsic difficulties of exploring NMS in ASD in controlled studies accounts for the subsequent lack of available information. Based on recent reports and on our case report, clinical features of NMS in the pediatric ASD population appear to be the same as the non-ASD population. Further studies are needed to confirm these results.
抗精神病药恶性综合征（NMS）是一种罕见的、危及生命的、对抗精神病药物的特异质性不良反应。尽管自闭症谱系障碍（ASD）儿科患者中抗精神病药物的处方率不断上升，但对于该特定人群中NMS的发生情况和特征却知之甚少。基于ASD与紧张症之间的频繁关联、与恶性紧张症共享（即便并非完全重叠）的临床特征，以及紧张症治疗对NMS/恶性紧张症症状的有效性，NMS似乎是更广泛的紧张症范畴的一部分。在对照研究中探索ASD患者的NMS存在内在困难，这导致了后续可用信息的匮乏。根据近期报告以及我们的病例报告，儿科ASD人群中NMS的临床特征似乎与非ASD人群相同。需要进一步研究来证实这些结果。
